888720-27-2

Upstream product

• 369-34-6 3,4-difluoronitrobenzene 
• 1221714-43-7 4-(t-butyldimethylsilyloxy)pyrrolo[1,2-b]pyridazine 
• 156335-37-4 ethyl 1,4-dihydro-4-oxopyrrolo<1,2-b>pyridazine-3-carboxylate 
• 888720-26-1 pyrrolo[1,2-b]pyridazin-4(1H)-one 
• 156335-36-3 diethyl (1-pyrrolyl)aminomethylenepropanedioate 
• 156335-30-7 1,4-dihydro-4-oxopyrrolo<1,2-b>pyridazine-3-carboxylic acid 

Downstream Products

• 1221714-55-1 1-(4-(2-fluoro-4-nitrophenoxy)pyrrolo[1,2-b]pyridazin-5-yl)ethanone 
• 1221714-45-9 4-(5-bromopyrrolo[1,2-b]pyridazin-4-yloxy)-3-fluoroaniline 
• 1221713-69-4 N-(4-(5-bromopyrrolo[1,2-b]pyridazin-4-yloxy)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1221714-44-8 5-bromo-4-(2-fluoro-4-nitrophenoxy)pyrrolo[1,2-b]pyridazine 
• 1221713-71-8 N-(3-fluoro-4-(5-phenylpyrrolo[1,2-b]pyridazin-4-yloxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 

Relevant academic research and scientific papers

Protein kinase inhibitors comprising a pyrrolopyridazine derivative

The present invention relates to a pyrrolopyridazine derivative represented by chemical formula 1, or a pharmaceutically acceptable salt of the same. A compound according to the present invention and a pharmaceutically acceptable salt of the same can be u

Protein kinase inhibitors comprising a pyrrolopyridazine derivative

The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt the

PROTEIN KINASE INHIBITOR CONTAINING PYRROLOPYRIDAZINE DERIVATIVE

The present invention relates to a pyrrolopyridazine derivative represented by Formula 1 of the detailed description, or a pharmaceutically acceptable salt thereof. The compound according to the present invention and a pharmaceutically acceptable salt the

HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR

Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.